Calculus has launched a £10m fundraise offer for its VCT, set to close on 30 August 2024.
The offer is accompanied by an over-allotment facility of up to £10m, bringing the total fundraise to a potential £20m. Calculus VCT offers investors a portfolio targeting sectors including technology, healthcare and entertainment, and currently holds Oxford BioTherapeutics, Optalix and Rotageek as part of the fund. Calculus capitalises on lifted EIS sunset clause with new fund The offer has a minimum investment threshold of £5,000, and the managers hope to attract "seasoned and new investors". John Glencross, chief executive and co-founder of Calculus Capital, said: "Our journe...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
